GlobalData on MSN1d
EMA CHMP recommends MSD’s KEYTRUDA for gynaecological cancers
Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...
BioSpace6d
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Keytruda keys in on survival: Promising results in high-risk early-stage TNBC from KEYNOTE-522
In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...
STAT8d
After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do
After 10 years of game-changing immunotherapies like Keytruda and Opdivo, a cancer conference celebrates — and sees more work ...
Iranian Immigrant Becomes Billionaire As Her Biotech Firm’s Stock Soars
Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
Cancer Therapy Advisor5d
Keytruda Plus Chemotherapy Approved for Malignant Pleural Mesothelioma
The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.
Pharmabiz2d
EU CHMP recommends approval of Merck’s Keytruda regimens as treatment for patients with two types of gynaecologic cancers
EU CHMP recommends approval of Merck’s Keytruda regimens as treatment for patients with two types of gynaecologic cancers ...
kpvi6d
Post-Op Keytruda Boosts Bladder Cancer Outcomes
Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...
Daily1d
USFDA nod to Merck KEYTRUDA plus Pemetrexed, Platinum Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S.Food and Drug Administration (FDA) ...
FiercePharma11d
Fierce Pharma Asia—Akeso, Summit's Keytruda-beating data; BIOSECURE's House passage; Candid's $370M debut
Akeso and Summit Therapeutics' ivonescimab showed strong efficacy against Merck's Keytruda in a phase 3 trial in China. The ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...